HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application
Abstract Background Gliflozins and gliptins are two distinct groups of pharmacological drugs that reduce blood glucose levels in individuals with type II diabetes in various ways that may perform their functions harmoniously. Trijardy® tablet, which contains empagliflozin, linagliptin, and metformin...
| Autors principals: | , , , , |
|---|---|
| Format: | Article |
| Idioma: | English |
| Publicat: |
BMC
2023-03-01
|
| Col·lecció: | BMC Chemistry |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s13065-023-00927-0 |